603590 康辰药业
已收盘 07-03 15:00:00
资讯
新帖
简况
康辰药业(603590.SH)拟推2026年限制性股票激励计划
智通财经 · 07-03 20:56
康辰药业(603590.SH)拟推2026年限制性股票激励计划
康辰药业涨5.34%,山西证券一个月前给出“买入”评级
证券之星 · 07-01
康辰药业涨5.34%,山西证券一个月前给出“买入”评级
康辰药业(603590)披露2025年年度权益分派实施公告,6月30日股价下跌3.3%
证券之星 · 06-30
康辰药业(603590)披露2025年年度权益分派实施公告,6月30日股价下跌3.3%
康辰药业涨6.65%,山西证券一个月前给出“买入”评级
证券之星 · 06-29
康辰药业涨6.65%,山西证券一个月前给出“买入”评级
每周股票复盘:康辰药业(603590)2025年净利增92%
证券之星 · 06-28
每周股票复盘:康辰药业(603590)2025年净利增92%
康辰药业(603590)披露2023年限制性股票激励计划部分解除限售条件成就公告,6月23日股价上涨4.18%
证券之星 · 06-23
康辰药业(603590)披露2023年限制性股票激励计划部分解除限售条件成就公告,6月23日股价上涨4.18%
每周股票复盘:康辰药业(603590)调整2025年分红总额
证券之星 · 06-20
每周股票复盘:康辰药业(603590)调整2025年分红总额
康辰药业(603590)披露调整2025年年度利润分配现金分红总额公告,6月16日股价下跌1.48%
证券之星 · 06-16
康辰药业(603590)披露调整2025年年度利润分配现金分红总额公告,6月16日股价下跌1.48%
每周股票复盘:康辰药业(603590)股份回购已支付6322万元
证券之星 · 06-07
每周股票复盘:康辰药业(603590)股份回购已支付6322万元
康辰药业(603590)披露股份回购进展公告,6月2日股价下跌4.04%
证券之星 · 06-02
康辰药业(603590)披露股份回购进展公告,6月2日股价下跌4.04%
每周股票复盘:康辰药业(603590)KC1036治疗晚期胸腺肿瘤数据将亮相ASCO
证券之星 · 05-31
每周股票复盘:康辰药业(603590)KC1036治疗晚期胸腺肿瘤数据将亮相ASCO
康辰药业最新公告:KC1036治疗晚期胸腺肿瘤数据将在2026年ASCO年会展示
证券之星 · 05-28
康辰药业最新公告:KC1036治疗晚期胸腺肿瘤数据将在2026年ASCO年会展示
山西证券:给予康辰药业买入评级
证券之星 · 05-28
山西证券:给予康辰药业买入评级
康辰药业涨10.01%,太平洋三周前给出“买入”评级
证券之星 · 05-21
康辰药业涨10.01%,太平洋三周前给出“买入”评级
异动快报:康辰药业(603590)5月21日13点7分触及涨停板
证券之星 · 05-21
异动快报:康辰药业(603590)5月21日13点7分触及涨停板
每周股票复盘:康辰药业(603590)股东会通过利润分配等六项议案
证券之星 · 05-17
每周股票复盘:康辰药业(603590)股东会通过利润分配等六项议案
康辰药业(603590)披露2025年年度股东会决议公告,5月14日股价下跌1.71%
证券之星 · 05-14
康辰药业(603590)披露2025年年度股东会决议公告,5月14日股价下跌1.71%
每周股票复盘:康辰药业(603590)回购进展及年度股东会将召开
证券之星 · 05-10
每周股票复盘:康辰药业(603590)回购进展及年度股东会将召开
康辰药业(603590)披露2025年年度股东会会议资料,5月7日股价上涨0.09%
证券之星 · 05-07
康辰药业(603590)披露2025年年度股东会会议资料,5月7日股价上涨0.09%
每周股票复盘:康辰药业(603590)股东户数增29.66%
证券之星 · 04-26
每周股票复盘:康辰药业(603590)股东户数增29.66%
加载更多
公司概况
公司名称:
北京康辰药业股份有限公司
所属行业:
医药制造业
上市日期:
2018-08-27
主营业务:
北京康辰药业股份有限公司的主营业务是创新药研发、生产与销售。公司的主要产品是注射用尖吻蝮蛇血凝酶、鲑降钙素注射液、鲑降钙素鼻用喷雾剂。公司凭借核心产品“注射用尖吻蝮蛇血凝酶”(商品名“苏灵”)荣获第八批国家级制造业单项冠军企业认定。报告期公司被授予“北京制造业企业百强”、“北京高精尖企业百强”、“北京专精特新企业百强”等荣誉资质,并通过高新技术企业重新认定,公司总裁牛战旗获“密云区首批高层次人才”称号,企业实力再获认可。
发行价格:
24.34
{"stockData":{"symbol":"603590","market":"SH","secType":"STK","nameCN":"康辰药业","latestPrice":31.71,"timestamp":1783062000000,"preClose":31.15,"halted":0,"volume":3186100,"delay":0,"changeRate":0.018,"floatShares":158000000,"shares":159000000,"eps":1.0609,"marketStatus":"已收盘","change":0.56,"latestTime":"07-03 15:00:00","open":31.15,"high":31.98,"low":30.84,"amount":100000000,"amplitude":0.0366,"askPrice":31.72,"askSize":17,"bidPrice":31.71,"bidSize":209,"shortable":0,"etf":0,"ttmEps":1.0609,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":31.15,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":34.27,"lowLimit":28.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":159010477,"isCdr":false,"pbRate":1.57,"roa":"--","peRate":29.889716,"roe":"1.46%","epsLYR":1.05,"committee":0.840108,"marketValue":5042000000,"turnoverRate":0.0201,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-06。","floatMarketCap":5017000000},"requestUrl":"/m/hq/s/603590","defaultTab":"news","newsList":[{"id":"2648766625","title":"康辰药业(603590.SH)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2648766625","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648766625?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:56","pubTimestamp":1783083400,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康辰药业(603590.SH)披露2026年限制性股票激励计划(草案),拟向激励对象授予的限制性股票数量为245.5万股,占激励计划草案公告时公司股本总额的1.54%。其中首次授予227.5万股,预留授予18万股。拟首次授予的激励对象总人数为63人。授予限制性股票的授予价格(含预留)为15.75元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515749","title":"康辰药业涨5.34%,山西证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515749?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:36","pubTimestamp":1782894965,"startTime":"0","endTime":"0","summary":"今日康辰药业涨5.34%,收盘报30.56元。2026年5月28日,山西证券研究员邓周宇,魏赟,张智勇发布了对康辰药业的研报《KAT6/7双靶点新药竞争力突出,KC1036临床提速》,该研报对康辰药业给出“买入”评级。研报中预计2026-2028年公司营收分别为10.07/11.15/12.95亿元,归母净利润1.87/2.11/2.51亿元,对应5月27日收盘价,PE为30.4/26.9/22.6倍,持续覆盖,给予“买入-B”评级。此外,太平洋研究员谭紫媚,张懿,中航证券研究员李蔚近期也对该股发布了研报,同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002500","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647552475","title":"康辰药业(603590)披露2025年年度权益分派实施公告,6月30日股价下跌3.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647552475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647552475?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:32","pubTimestamp":1782829939,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,康辰药业报收于29.01元,较前一交易日下跌3.3%,最新总市值为46.13亿元。该股当日开盘29.63元,最高30.08元,最低28.6元,成交额达9507.5万元,换手率为2.06%。近日,康辰药业发布《2025年年度权益分派实施公告》:每股现金红利0.35元(含税),股权登记日为2026年7月7日,除权(息)日及现金红利发放日均为2026年7月8日。公司总股本159,010,477股,扣除回购股份及待回购注销的限制性股票后实施差异化分红。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000047270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324174","title":"康辰药业涨6.65%,山西证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647324174?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:33","pubTimestamp":1782721989,"startTime":"0","endTime":"0","summary":"今日康辰药业涨6.65%,收盘报30.0元。2026年5月28日,山西证券研究员邓周宇,魏赟,张智勇发布了对康辰药业的研报《KAT6/7双靶点新药竞争力突出,KC1036临床提速》,该研报对康辰药业给出“买入”评级。研报中预计2026-2028年公司营收分别为10.07/11.15/12.95亿元,归母净利润1.87/2.11/2.51亿元,对应5月27日收盘价,PE为30.4/26.9/22.6倍,持续覆盖,给予“买入-B”评级。此外,太平洋研究员谭紫媚,张懿,中航证券研究员李蔚近期也对该股发布了研报,同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","002500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646481315","title":"每周股票复盘:康辰药业(603590)2025年净利增92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646481315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646481315?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:34","pubTimestamp":1782588853,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,康辰药业报收于28.13元,较上周的29.47元下跌4.55%。本周,康辰药业6月24日盘中最高价报30.89元。本周关注点公司公告汇总:康辰药业2025年净利润增长率达92%,满足股权激励解除限售条件。公司公告汇总:康辰药业本次合计解除限售773,600股,约占公司总股本的0.49%。公司未发生不得实行股权激励的情形,激励对象未发生不得参与股权激励的情形,2025年净利润增长率达92%,满足业绩考核要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645983245","title":"康辰药业(603590)披露2023年限制性股票激励计划部分解除限售条件成就公告,6月23日股价上涨4.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645983245","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645983245?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:24","pubTimestamp":1782224666,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘,康辰药业报收于30.41元,较前一交易日上涨4.18%,最新总市值为48.36亿元。近日,康辰药业发布《关于公司2023年限制性股票激励计划首次授予部分第三个解除限售期及预留授予部分第二个解除限售期解除限售条件成就的公告》。公告显示,公司于2026年6月23日召开第五届董事会第三次会议,审议通过相关议案。公司层面业绩考核达标,2025年净利润增长率达92%,满足解除限售条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644065315","title":"每周股票复盘:康辰药业(603590)调整2025年分红总额","url":"https://stock-news.laohu8.com/highlight/detail?id=2644065315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644065315?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:45","pubTimestamp":1781894712,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,康辰药业报收于29.47元,较上周的29.93元下跌1.54%。本周,康辰药业6月15日盘中最高价报30.09元。康辰药业当前最新总市值46.86亿元,在生物制品板块市值排名41/51,在两市A股市值排名3421/5206。本周关注点来自公司公告汇总:康辰药业因回购股份增加导致可分配股本减少,实际派发金额由55,135,245.55元调整为54,952,335.55元(含税)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643775955","title":"康辰药业(603590)披露调整2025年年度利润分配现金分红总额公告,6月16日股价下跌1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643775955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643775955?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:52","pubTimestamp":1781607134,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,康辰药业报收于29.34元,较前一交易日下跌1.48%,最新总市值为46.65亿元。该股当日开盘29.51元,最高29.6元,最低29.15元,成交额达4983.18万元,换手率为1.07%。近日,康辰药业发布《关于调整2025年年度利润分配现金分红总额的公告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600036684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641412784","title":"每周股票复盘:康辰药业(603590)股份回购已支付6322万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641412784","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641412784?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:58","pubTimestamp":1780768690,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘,康辰药业报收于30.44元,较上周的34.45元下跌11.64%。本周,康辰药业6月1日盘中最高价报34.99元。康辰药业关于股份回购进展公告北京康辰药业股份有限公司于2025年10月15日召开董事会审议通过回购股份方案,拟以集中竞价交易方式回购股份,用于员工持股计划或股权激励。截至2026年5月31日,已累计回购1,476,204股,占公司总股本的0.93%,回购最高价51.40元/股,最低价36.42元/股,已支付总金额63,225,426.08元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640914686","title":"康辰药业(603590)披露股份回购进展公告,6月2日股价下跌4.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640914686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640914686?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:09","pubTimestamp":1780394966,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘,康辰药业报收于32.81元,较前一交易日下跌4.04%,最新总市值为52.17亿元。公司于近日披露《关于股份回购进展公告》。公告显示,北京康辰药业股份有限公司于2025年10月15日召开董事会审议通过回购股份方案,拟以集中竞价交易方式回购股份,用于员工持股计划或股权激励。截至2026年5月31日,已累计回购1,476,204股,占公司总股本的0.93%,回购最高价51.40元/股,最低价36.42元/股,已支付总金额63,225,426.08元。本次回购符合相关规定和方案要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200036008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639860447","title":"每周股票复盘:康辰药业(603590)KC1036治疗晚期胸腺肿瘤数据将亮相ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2639860447","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639860447?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:53","pubTimestamp":1780170789,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,康辰药业报收于34.45元,较上周的37.76元下跌8.77%。本周,康辰药业5月25日盘中最高价报38.7元。康辰药业当前最新总市值54.78亿元,在生物制品板块市值排名40/51,在两市A股市值排名3166/5207。该研究共入组31例患者,其中胸腺癌25例,胸腺瘤6例。截至2025年6月9日,胸腺癌患者的客观缓解率为20.0%,疾病控制率为80%,中位无进展生存期为8.2个月,中位缓解持续时间为15.3个月;胸腺瘤患者DCR为100%,中位PFS为13.6个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667264","title":"康辰药业最新公告:KC1036治疗晚期胸腺肿瘤数据将在2026年ASCO年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667264","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638667264?lang=zh_cn&edition=full","pubTime":"2026-05-28 19:01","pubTimestamp":1779966060,"startTime":"0","endTime":"0","summary":"康辰药业(603590.SH)公告称,公司自主研发的KC1036片将于2026年美国临床肿瘤学会(ASCO)年会以壁报形式展示治疗既往含铂化疗后进展的晚期胸腺肿瘤的II期临床研究数据。研究显示,胸腺癌患者客观缓解率为20%,疾病控制率为80%,中位无进展生存期为8.2个月;胸腺瘤患者疾病控制率为100%,中位无进展生存期为13.6个月。未观察到新的安全性信号。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800036281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638657764","title":"山西证券:给予康辰药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2638657764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638657764?lang=zh_cn&edition=full","pubTime":"2026-05-28 14:25","pubTimestamp":1779949532,"startTime":"0","endTime":"0","summary":"山西证券股份有限公司邓周宇,魏赟,张智勇近期对康辰药业进行研究并发布了研究报告《KAT6/7双靶点新药竞争力突出,KC1036临床提速》,给予康辰药业买入评级。 康辰药业 公司点评 公司覆盖出凝血、肿瘤等疾病领域。KC1086为全球首创KAT6/7双靶点药物,经AACR壁报数据佐证,具备同类最优潜力。最新盈利预测明细如下:该股最近90天内共有11家机构给出评级,买入评级8家,增持评级3家;过去90天内机构目标均价为41.76。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800021595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","002500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637638308","title":"康辰药业涨10.01%,太平洋三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2637638308","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637638308?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:28","pubTimestamp":1779352116,"startTime":"0","endTime":"0","summary":"今日康辰药业涨10.01%,收盘报39.22元。2026年4月29日,太平洋研究员谭紫媚,张懿发布了对康辰药业的研报《康辰药业:核心产品增长稳健,创新管线快速推进》,该研报对康辰药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为61.07%。此外,中航证券研究员李蔚,中银证券研究员刘恩阳,苏雪儿近期也对该股发布了研报,同样给出“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100030323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637072809","title":"异动快报:康辰药业(603590)5月21日13点7分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2637072809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637072809?lang=zh_cn&edition=full","pubTime":"2026-05-21 13:15","pubTimestamp":1779340532,"startTime":"0","endTime":"0","summary":"证券之星5月21日盘中消息,13点7分康辰药业触及涨停板。其所属行业生物制品目前上涨。该股为创新药,医药,化学原料药概念热股,当日创新药概念上涨1.54%,医药概念上涨0.75%,化学原料药概念上涨0.55%。5月20日的资金流向数据方面,主力资金净流入219.04万元,占总成交额1.87%,游资资金净流入831.29万元,占总成交额7.09%,散户资金净流出1050.34万元,占总成交额8.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100021436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636417064","title":"每周股票复盘:康辰药业(603590)股东会通过利润分配等六项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2636417064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636417064?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:36","pubTimestamp":1778960173,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,康辰药业报收于35.09元,较上周的35.62元下跌1.49%。本周关注点来自公司公告汇总:康辰药业2025年年度股东会审议通过利润分配预案等六项议案,全部获通过。北京康辰药业股份有限公司于2026年5月14日召开2025年年度股东会,会议由董事长刘建华主持,采用现场与网络投票相结合方式召开。北京康辰药业股份有限公司于2025年10月29日召开董事会及监事会,审议通过使用不超过2.6亿元闲置募集资金进行现金管理的议案,有效期12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745087","title":"康辰药业(603590)披露2025年年度股东会决议公告,5月14日股价下跌1.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745087","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635745087?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:37","pubTimestamp":1778769433,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘,康辰药业报收于35.65元,较前一交易日下跌1.71%,最新总市值为56.69亿元。该股当日开盘36.2元,最高36.63元,最低35.42元,成交额达8461.46万元,换手率为1.5%。近日,康辰药业发布《2025年年度股东会决议公告》。公告显示,公司于2026年5月14日召开2025年年度股东会,会议由董事长刘建华主持,采用现场与网络投票相结合方式召开。出席会议股东及代理人共333人,代表有表决权股份77,371,827股,占公司有表决权股份总数的49.1143%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400043191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634441453","title":"每周股票复盘:康辰药业(603590)回购进展及年度股东会将召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2634441453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634441453?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:21","pubTimestamp":1778350870,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,康辰药业报收于35.62元,较上周的35.4元上涨0.62%。本周,康辰药业5月8日盘中最高价报36.08元。本周关注点公司公告汇总:康辰药业将于2026年5月14日召开2025年年度股东会。公司公告汇总:截至2026年4月30日,康辰药业已累计回购1,476,204股,支付金额63,225,426.08元。康辰药业关于股份回购进展公告北京康辰药业股份有限公司于2025年10月15日召开董事会审议通过回购股份方案,拟以集中竞价交易方式回购股份,用于员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633126044","title":"康辰药业(603590)披露2025年年度股东会会议资料,5月7日股价上涨0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633126044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633126044?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:58","pubTimestamp":1778165893,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘,康辰药业报收于35.09元,较前一交易日上涨0.09%,最新总市值为55.8亿元。近日,康辰药业发布《2025年年度股东会会议资料》公告。公告显示,公司将于2026年5月14日召开2025年年度股东会,会议审议2025年度董事会工作报告、利润分配预案、董事及高管薪酬管理制度修订、续聘华兴会计师事务所为2026年度审计机构、回购注销部分限制性股票等议案,并听取独立董事述职报告及高级管理人员薪酬执行情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630044018","title":"每周股票复盘:康辰药业(603590)股东户数增29.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630044018","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630044018?lang=zh_cn&edition=full","pubTime":"2026-04-26 04:06","pubTimestamp":1777147572,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,康辰药业报收于35.25元,较上周的38.61元下跌8.7%。本周,康辰药业4月20日盘中最高价报38.59元。股本股东变化股东户数变动截至2026年3月31日,康辰药业股东户数为1.52万户,较2025年12月31日增加3486.0户,增幅达29.66%。回购注销后,公司总股本将由159,010,477股减少至159,005,477股。康辰药业关于公司在2026年AACR年会展示创新药KC1086和KC1101临床前研究数据的公告2026年4月21日,公司在AACR年会上以壁报形式首次公布自主研发创新药KC1086和KC1101的临床前研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783177784889,"stockEarnings":[{"period":"1week","weight":0.1273},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.1598},{"period":"6month","weight":-0.2023},{"period":"1year","weight":-0.0469},{"period":"ytd","weight":-0.2023}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京康辰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15241人(较上一季度增加29.66%)","perCapita":"10381股","listingDate":"2018-08-27","address":"北京市密云区经济开发区兴盛南路11号","registeredCapital":"15901万元","survey":" 北京康辰药业股份有限公司的主营业务是创新药研发、生产与销售。公司的主要产品是注射用尖吻蝮蛇血凝酶、鲑降钙素注射液、鲑降钙素鼻用喷雾剂。公司凭借核心产品“注射用尖吻蝮蛇血凝酶”(商品名“苏灵”)荣获第八批国家级制造业单项冠军企业认定。报告期公司被授予“北京制造业企业百强”、“北京高精尖企业百强”、“北京专精特新企业百强”等荣誉资质,并通过高新技术企业重新认定,公司总裁牛战旗获“密云区首批高层次人才”称号,企业实力再获认可。","listedPrice":24.34},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康辰药业,603590,康辰药业股票,康辰药业股票老虎,康辰药业股票老虎国际,康辰药业行情,康辰药业股票行情,康辰药业股价,康辰药业股市,康辰药业股票价格,康辰药业股票交易,康辰药业股票购买,康辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}